Curcumin Reduces Prostaglandin E2, Matrix Metalloproteinase-3 and Proteoglycan Release in the Secretome of Interleukin 1β-treated Articular Cartilage

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2014 Feb 25

PMID 24555068

Citations 24

Authors

Abigail L Clutterbuck

David Allaway

Pat Harris

Ali Mobasheri

Affiliations

Soon will be listed here.

Abstract

Objective: Curcumin (diferuloylmethane) is a phytochemical with potent anti-inflammatory and anti-oxidant properties, and has therapeutic potential for the treatment of a range of inflammatory diseases, including osteoarthritis (OA). The aim of this study was to determine whether non-toxic concentrations of curcumin can reduce interleukin-1beta (IL-1β)-stimulated inflammation and catabolism in an explant model of cartilage inflammation.

Methods: Articular cartilage explants and primary chondrocytes were obtained from equine metacarpophalangeal joints. Curcumin was added to monolayer cultured primary chondrocytes and cartilage explants in concentrations ranging from 3μM-100μM. Prostaglandin E 2 (PGE 2) and matrix metalloproteinase (MMP)-3 release into the secretome of IL-1β-stimulated explants was measured using a competitive ELISA and western blotting respectively. Proteoglycan (PG) release in the secretome was measured using the 1,9-dimethylmethylene blue (DMMB) assay. Cytotoxicity was assessed with a live/dead assay in monolayer cultures after 24 hours, 48 hours and five days, and in explants after five days.

Results: Curcumin induced chondrocyte death in primary cultures (50μM p<0.001 and 100μM p<0.001) after 24 hours. After 48 hours and five days, curcumin (≥25μM) significantly increased cell death ( p<0.001 both time points). In explants, curcumin toxicity was not observed at concentrations up to and including 25μM after five days. Curcumin (≥3μM) significantly reduced IL-1β-stimulated PG ( p<0.05) and PGE 2 release ( p<0.001) from explants, whilst curcumin (≥12μM) significantly reduced MMP-3 release ( p<0.01).

Conclusion: Non-cytotoxic concentrations of curcumin exert anti-catabolic and anti-inflammatory effects in cartilage explants.

Citing Articles

Nutritional Epigenomics: Bioactive Dietary Compounds in the Epigenetic Regulation of Osteoarthritis.

Villagran-Andrade K, Nunez-Carro C, Blanco F, de Andres M Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338311 PMC: 11434976. DOI: 10.3390/ph17091148.

Natural Compounds: Potential Therapeutics for the Inhibition of Cartilage Matrix Degradation in Osteoarthritis.

Ashruf O, Ansari M Life (Basel). 2023; 13(1).

PMID: 36676051 PMC: 9866583. DOI: 10.3390/life13010102.

Potential complementary and/or synergistic effects of curcumin and boswellic acids for management of osteoarthritis.

Sethi V, Garg M, Herve M, Mobasheri A Ther Adv Musculoskelet Dis. 2022; 14:1759720X221124545.

PMID: 36171802 PMC: 9511324. DOI: 10.1177/1759720X221124545.

Phytochemicals Mediate Autophagy Against Osteoarthritis by Maintaining Cartilage Homeostasis.

Tian Z, Zhang X, Sun M Front Pharmacol. 2022; 12:795058.

PMID: 34987406 PMC: 8722717. DOI: 10.3389/fphar.2021.795058.

Mechanisms and Pharmaceutical Action of Lipid Nanoformulation of Natural Bioactive Compounds as Efficient Delivery Systems in the Therapy of Osteoarthritis.

Craciunescu O, Icriverzi M, Florian P, Roseanu A, Trif M Pharmaceutics. 2021; 13(8).

PMID: 34452068 PMC: 8399940. DOI: 10.3390/pharmaceutics13081108.

References

Ohta S, Imai K, Yamashita K, Matsumoto T, Azumano I, Okada Y . Expression of matrix metalloproteinase 7 (matrilysin) in human osteoarthritic cartilage. Lab Invest. 1998; 78(1):79-87. View

Blanco F, Lotz M . IL-1-induced nitric oxide inhibits chondrocyte proliferation via PGE2. Exp Cell Res. 1995; 218(1):319-25. DOI: 10.1006/excr.1995.1161. View

Csaki C, Mobasheri A, Shakibaei M . Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther. 2009; 11(6):R165. PMC: 3003513. DOI: 10.1186/ar2850. View

Brouet I, Ohshima H . Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun. 1995; 206(2):533-40. DOI: 10.1006/bbrc.1995.1076. View

Maiotti M, Monteleone G, Tarantino U, Fasciglione G, Marini S, Coletta M . Correlation between osteoarthritic cartilage damage and levels of proteinases and proteinase inhibitors in synovial fluid from the knee joint. Arthroscopy. 2000; 16(5):522-6. DOI: 10.1053/jars.2000.4632. View

Fosang A, Last K, Knauper V, Neame P, Murphy G, Hardingham T . Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. Biochem J. 1993; 295 ( Pt 1):273-6. PMC: 1134849. DOI: 10.1042/bj2950273. View

Julovi S, Yasuda T, Shimizu M, Hiramitsu T, Nakamura T . Inhibition of interleukin-1beta-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum. 2004; 50(2):516-25. DOI: 10.1002/art.20004. View

Toegel S, Wu S, Piana C, Unger F, Wirth M, Goldring M . Comparison between chondroprotective effects of glucosamine, curcumin, and diacerein in IL-1beta-stimulated C-28/I2 chondrocytes. Osteoarthritis Cartilage. 2008; 16(10):1205-12. DOI: 10.1016/j.joca.2008.01.013. View

Shiomi T, Lemaitre V, DArmiento J, Okada Y . Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathol Int. 2010; 60(7):477-96. PMC: 3745773. DOI: 10.1111/j.1440-1827.2010.02547.x. View

10.

Hui W, Rowan A, Richards C, Cawston T . Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum. 2003; 48(12):3404-18. DOI: 10.1002/art.11333. View

11.

Garcia A, Frank E, Grimshaw P, Grodzinsky A . Contributions of fluid convection and electrical migration to transport in cartilage: relevance to loading. Arch Biochem Biophys. 1996; 333(2):317-25. DOI: 10.1006/abbi.1996.0397. View

12.

Mathy-Hartert M, Jacquemond-Collet I, Priem F, Sanchez C, Lambert C, Henrotin Y . Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res. 2009; 58(12):899-908. DOI: 10.1007/s00011-009-0063-1. View

13.

Dvorak L, Cook J, Kreeger J, Kuroki K, Tomlinson J . Effects of carprofen and dexamethasone on canine chondrocytes in a three-dimensional culture model of osteoarthritis. Am J Vet Res. 2002; 63(10):1363-9. DOI: 10.2460/ajvr.2002.63.1363. View

14.

Ahmed S, Anuntiyo J, Malemud C, Haqqi T . Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis: a review. Evid Based Complement Alternat Med. 2005; 2(3):301-8. PMC: 1193557. DOI: 10.1093/ecam/neh117. View

15.

Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A . Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology. 2007; 5:3. PMC: 1868037. DOI: 10.1186/1477-3155-5-3. View

16.

Chu C, Izzo N, Papas N, Fu F . In vitro exposure to 0.5% bupivacaine is cytotoxic to bovine articular chondrocytes. Arthroscopy. 2006; 22(7):693-9. DOI: 10.1016/j.arthro.2006.05.006. View

17.

Okada Y, Shinmei M, Tanaka O, Naka K, Kimura A, Nakanishi I . Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest. 1992; 66(6):680-90. View

18.

Farndale R, Sayers C, Barrett A . A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res. 1982; 9(4):247-8. DOI: 10.3109/03008208209160269. View

19.

Chubinskaya S, Huch K, Mikecz K, Cs-Szabo G, Hasty K, Kuettner K . Chondrocyte matrix metalloproteinase-8: up-regulation of neutrophil collagenase by interleukin-1 beta in human cartilage from knee and ankle joints. Lab Invest. 1996; 74(1):232-40. View

20.

Moon Y, Glasgow W, Eling T . Curcumin suppresses interleukin 1beta-mediated microsomal prostaglandin E synthase 1 by altering early growth response gene 1 and other signaling pathways. J Pharmacol Exp Ther. 2005; 315(2):788-95. DOI: 10.1124/jpet.105.084434. View